[1]WANG FS,FAN JG,ZHANG Z,et al.The global burden of liver disease:the major impact of China[J].Hepatology,2014,60(6):2099-2108.
|
[2] FAN JG.Epidemiology of alcoholic and nonalcoholic fatty liver disease in China[J].J Gastroenterol Hepatol,2013,28(Suppl 1):11-17.
|
[3] RINELLA ME.Nonalcoholic fatty liver disease:a systematic review[J].JAMA,2015,313(22):2263-2273.
|
[4]BYRNE CD,TARGHER G.NAFLD:A multisystem disease[J].J Hepatol,2015,62(Suppl 1):s47-s65.
|
[5]NASCIMBENI F,PAIS R,BELLENTANI S,et al.From NAFLD in clinical practice to answers from guidelines[J].J Hepatol,2013,59(4):859-871.
|
[6]O'SHEA RS,DASARATHY S,Mc CULLOUGH AJ.Alcoholic liver disease.AASLD practice guideline[J].Hepatology,2010,105(1):307-328.
|
[7]GU D,REYNOLDS K,WU X,et al.Prevalence of the metabolic syndrome and overweight among adults in China[J].Lancet,2005,365(9468):1398-1405.
|
[8]FAN JG,PENG YD.Metabolic syndrome and non-alcoholic fatty liver disease:Asian definitions and Asian studies[J].Hepatobiliary Pancreat Dis Int,2007,6(6):572-578.
|
[9]FAN JG,SAIBARA T,CHITTURI S,et al.What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific?[J].J Gastroenterol Hepatol,2007,22(6):794-800.
|
[10] XU C,YU CH,MA H,et al.Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population:the Zhejiang Zhenhai Study[J].Am J Gastroenterol,2013,108(8):1299-1304.
|
[11]ALBELDAWI M,AGGARWAL A,MADHWAL S,et al.Cumulative risk of cardiovascular events after orthotopic liver transplantation[J].Liver Transpl,2012,18(3):370-375.
|
[12]AGRAWAL S,DARUWALA C.Metabolic syndrome and hepatic resection:improving outcome[J].HPB(Oxford),2011,13(12):846-859.
|
[13]FAN JG,CAI XB,LI L,et al.Alcohol consumption and metabolic syndrome among Shanghai adults:a randomized multistage stratified cluster sampling investigation[J].World J Gastroenterol,2008,14(15):2418-2424.
|
[14]GUNJI T,MATSUHASHI N,SATO H,et al.Alcohol consumption is inversely correlated with insulin resistance,independent of metabolic syndrome factors and fatty liver diseases[J].J Clin Gastroenterol,2011,45(9):808-813.
|
[15]KIM JH,KIM SY,JUNG ES,et al.Carotid intima-media thickness is increased not only in non-alcoholic fatty liver disease patients but also in alcoholic fatty liver patients[J].Digestion,2011,84(2):149-155.
|
[16]BUGIANESI E,SALAMONE F,NEGRO F.The interaction of metabolic factors with HCV infection:does it matter?[J].J Hepatol,2012,56(Suppl 1):s56-s65.
|
[17]ADINOLFI LE,RESTIVO L,ZAMPINO R,et al.Chronic HCV infection is a risk of atherosclerosis.Role of HCV and HCV-related steatosis[J].Atherosclerosis,2012,221(2):496-502.
|
[18]FAN JG,CHITTURI S.Hepatitis B and fatty liver:causal or coincidental?[J].J Gastroenterol Hepatol,2008,23(5):779-782.
|
[19]HSU CS,LIU CH,WANG CC,et al.Impact of hepatitis B virus infection on metabolic profiles and modifying factors[J].J Viral Hepat,2012,19(2):e48-e57.
|
[20]WONG VW,WONG GL,CHU WC,et al.Hepatitis B virus infection and fatty liver in the general population[J].J Hepatol,2012,56(3):533-540.
|
[21]SHI JP,FAN JG,WU R,et al.Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection[J].J Gastroenterol Hepatol.2008,23(9):1419-1425.
|
[22]PAN Q,ZHANG RN,WANG YQ,et al.Linked polymorphisms of PNPLA3 confer susceptibility to nonalcoholic steatohepatitis and decreased viral load in chronic hepatitis B[J].World J Gastroenterol,2015,21(28):8605-8614.
|
[23]DING WJ,WANG MM,WANG GS,et al.Thyroid function is associated with non-alcoholic fatty liver disease in chronic hepatitis B infected subjects[J].J Gastroenterol Hepatol,2015,30(12):1753-1758.
|
[24]WANG MM,WANG GS,SHEN F,et al.Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors[J].Dig Dis Sci,2014,59(10):2571-2579.
|
[25] JIN X,CHEN YP,YANG YD,et al.Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B[J].PLo S One,2012,7(3):e34198.
|
[26]HSIANG JC,WONG GL,CHAN HL,et al.Metabolic syndrome delays HBe Ag seroclearance in Chinese patients with hepatitis B[J].Aliment Pharmacol Ther,2014,40(6):716-726.
|
[27]ZHANG Z,PAN Q,DUAN XY,et al.Fatty liver reduces hepatitis B virus replication in a genotype B hepatitis B virus transgenic mice model.Fatty liver reduces hepatitis B virus replication in a genotype B hepatitis B virus transgenic mice model[J].J Gastroenterol Hepatol,2012,27(12):1858-1864.
|
[28]ZHANG RN,PAN Q,ZHANG Z,et al.Saturated fatty acid inhibits viral replication in chronic HBV infection with nonalcoholic fatty liver disease by TLR4 mediated innate immune response[J].Hepat Mon,2015,15(5):e27909.
|
[29]CHU CM,LIN DY,LIAW YF.Clinical and virological characteristics post HBs Ag seroclearance in hepatitis B virus carriers with hepatic steatosis versus those without[J].Dig Dis Sci,2013,58(1):275-281.
|
[30]BORENA W,STROHMAIER S,LUKANOVA A,et al.Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults[J].Int J Cancer,2012,131(1):193-200.
|
[31]LIN CW,LIN CC,MO LR,et al.Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis[J].J Hepatol,2013,58(4):730-735.
|
[32]WELZEL TM,GRAUBARD BI,ZEUZEM S,et al.Metabolic syndrome increases the risk of primary liver cancer in the United States:a study in the SEER-Medicare database[J].Hepatology,2011,54(2):463-471.
|
[33]Asia-Pacific Working Party for Prevention of Hepatocellular Carcinoma.Prevention of hepatocellular carcinoma in non-viral related liver diseases[J].J Gastroenterol Hepatol,2009,25(4):712-719.
|
[34]NOBILI V,CARTER-KENT C,FELDSTEIN AE.The role of lifestyle changes in the management of chronic liver disease[J].BMC Med,2011,9(1):70.
|